- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03793608
Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
A Study to Evaluate the Efficacy and Safety of Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
The primary objective of the study is to assess the tolerability of peanut protein in pediatric patients (6-17 years old) treated with dupilumab monotherapy, in which tolerability is defined as the proportion of patients who safely pass a double-blind placebo-controlled food challenge (DBPCFC) at week 24.
The secondary objectives are:
- To determine whether dupilumab treatment improves peanut tolerability, defined as a change in the cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC
- To evaluate the safety and tolerability of dupilumab treatment in peanut allergic patients
- To evaluate the effects of dupilumab treatment on the levels of peanut-specific Immunoglobulin E (IgE)
- To evaluate the treatment effect of dupilumab on the average wheal size after a titrated skin prick test (SPT), as measured by area under curve (AUC) of the average wheal size induced by peanut extract at different concentrations
- To assess the incidence of treatment-emergent anti-drug antibodies (ADA) to dupilumab in patients over time
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S 1G5
- Regeneron Investigational Site
-
Toronto, Ontario, Canada, M5G 1X8
- Regeneron Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- Regeneron Investigational Site
-
-
-
-
California
-
Mountain View, California, United States, 94305
- Regeneron Investigational Site
-
-
Florida
-
Tampa, Florida, United States, 33612
- Regeneron Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Regeneron Investigational Site
-
-
Michigan
-
Ypsilanti, Michigan, United States, 48197
- Regeneron Investigational Site
-
-
New York
-
Bronx, New York, United States, 10461
- Regeneron Investigational Site
-
Great Neck, New York, United States, 11021
- Regeneron Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Patient has a clinical history of allergy to peanuts or peanut-containing foods (symptom[s] of reaction due to exposure).
- Experience dose-limiting symptoms at or before the challenge dose of peanut protein on screening DBPCFC conducted in accordance with Practical Issues in Allergology, Joint United States/European Union Initiative (PRACTALL) guidelines. And not experiencing dose limiting symptoms to placebo
- Serum IgE to peanut of ≥10 kilo units (kUA)/L and/or a SPT to peanut ≥8 mm compared to a negative control
- Patients/legal guardians must be trained on the proper use of the epinephrine autoinjector device to be allowed to enroll in the study
- Patients with other known food allergies must agree to eliminate these other food items from their diet so as not to confound the safety and efficacy data from the study
Key Exclusion Criteria:
- Any previous exposure to marketed dupilumab or dupilumab in a clinical trial
- Member of the clinical site study team or his/her immediate family
- History of other chronic disease (other than asthma, AD, or allergic rhinitis) requiring therapy
- History of frequent or recent severe, life-threatening episode of anaphylaxis or anaphylactic shock as defined by more than 3 episodes of anaphylaxis within the past year and/or an episode of anaphylaxis within 60 days of screening DBPCFC
- History of eosinophilic gastrointestinal disease
- History of eosinophilic granulomatosis with polyangiitis
- Severe, unstable asthma at time of enrollment or any patient with Forced Expiratory Volume in 1 Second (FEV1) <80% of predicted or asthma control questionnaire (ACQ)>1.5
- Use of systemic corticosteroids within 2 months prior to screening
Note: Other protocol Inclusion/Exclusion Criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dupilumab
Open label weight base subcutaneous (SC) injection every two (Q2) weeks.
|
Dupilumab weight-based dosing will be administered subcutaneously (SC) in a single-use, pre-filled syringe every two weeks (Q2W)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 24
Time Frame: At Week 24
|
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions.
The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction.
Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction.
Percentage of participants treated with dupilumab who passed the DBPCFC with at least 444 mg (cumulative) peanut protein at Week 24 was reported.
|
At Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Weeks 24 and 36
Time Frame: Weeks 24 and 36
|
Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Week 24 and Week 36 was reported.
|
Weeks 24 and 36
|
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 36
Time Frame: At Week 36
|
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions.
The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction.
Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction.
Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.
|
At Week 36
|
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 1044 mg (Cumulative) Peanut Protein at Week 24
Time Frame: At Week 24
|
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions.
The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction.
Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction.
Percentage of participants treated with dupilumab who passed a DBPCFC with at least 1044 mg (cumulative) peanut protein at Week 24 was reported.
|
At Week 24
|
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 1044 mg (Cumulative) Peanut Protein at Week 36
Time Frame: At Week 36
|
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions.
The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction.
Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction.
Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.
|
At Week 36
|
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 2044 mg (Cumulative) Peanut Protein at Week 24
Time Frame: At Week 24
|
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions.
The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction.
Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction.
Percentage of participants treated with dupilumab who passed a DBPCFC with at least 2044 mg (cumulative) peanut protein at Week 24 was reported.
|
At Week 24
|
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 2044 mg (Cumulative) Peanut Protein at Week 36
Time Frame: At Week 36
|
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions.
The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction.
Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction.
Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.
|
At Week 36
|
Percent Change From Baseline in Peanut-specific Immunoglobulin E (sIgE) at Weeks 4, 8, 12, 16, 24, and 36
Time Frame: Weeks 4, 8, 12, 16, 24, and 36
|
Percent change from baseline in sIgE at Weeks 4, 8, 12, 16, 24, and 36 was reported.
|
Weeks 4, 8, 12, 16, 24, and 36
|
Change From Baseline in Titrated Skin Prick Test (SPT) Measured by Average Wheal Size Area Under the Curve (AUC) After Peanut Allergen Stimulation at Different Concentrations at Weeks 4, 12, 24, and 36
Time Frame: Weeks 4, 12, 24, and 36
|
The titrated SPT is the skin testing for atopic response at different concentrations of peanut extract with saline as negative control and histamine as positive controls.
Wheal size induced by peanut extract at each concentration was calculated as average of largest diameter and perpendicular midpoint diameter.
The AUC for titrated SPT was calculated using the mean wheal diameter versus the concentration at which the wheal diameter was measured, which was then normalized to concentration.
Change from baseline in titrated SPT as measured by average wheal size AUC after peanut allergen stimulation at different concentrations at Weeks 4, 12, 24, and 36 was reported.
|
Weeks 4, 12, 24, and 36
|
Percentage of Participants With Grade 2 or Above Allergic Reactions During the DBPCFC at Week 24
Time Frame: At Week 24
|
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions.
The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction.
Percentage of participants with Grade 2 (Moderate) or above allergic reactions during the DBPCFC at Week 24 was reported.
|
At Week 24
|
Percentage of Participants Who Used Epinephrine as a Rescue Medication During the DBPCFC at Week 24
Time Frame: At Week 24
|
Percentage of participants who used Epinephrine as a rescue medication during the DBPCFC at Week 24 was reported.
|
At Week 24
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R668-ALG-1702
- 2018-003133-15 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peanut Allergy
-
Rima RachidUniversity of MinnesotaRecruitingPeanut Hypersensitivity | Peanut Allergy | Food Allergy | Food Allergy Peanut | Peanut-Induced Anaphylaxis | Allergy, PeanutUnited States
-
Scripps HealthThe Scripps Research InstituteWithdrawnFood Allergy PeanutUnited States
-
Novartis PharmaceuticalsTerminatedAllergy, PeanutUnited States, Germany, Japan, Australia, France, Spain, Denmark, Canada, Italy, Netherlands
-
University of ManitobaThe Hospital for Sick Children; University of British Columbia; McGill UniversityEnrolling by invitationAllergy to Peanut
-
Imperial College LondonUniversity of Sydney; National Institute for Health Research, United KingdomCompletedIgE Mediated Peanut AllergyUnited Kingdom
-
King's College LondonCharite University, Berlin, Germany; University Hospital, Bonn; Institut Curie; Levantine UKNot yet recruitingAllergy;Food | Food Allergy Peanut | Pathways and Sources of Exposure
-
Imperial College LondonUniversity College CorkActive, not recruitingPeanut Hypersensitivity | IgE Mediated Peanut AllergyUnited Kingdom
-
University of RochesterNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingEgg Allergy | Food Allergy Peanut | Food Allergy in Infants | Allergy and Immunology | Peanut and Nut AllergyUnited States
-
National Institute of Allergy and Infectious Diseases...Genentech, Inc.; Novartis Pharmaceuticals; Rho Federal Systems Division, Inc.Active, not recruitingPeanut Allergy | Multi-food AllergyUnited States
-
Scott SichererNational Institute of Allergy and Infectious Diseases (NIAID)CompletedPeanut Allergy | Food AllergyUnited States
Clinical Trials on Dupilumab
-
Brigham and Women's HospitalRegeneron PharmaceuticalsRecruiting
-
Akron Children's HospitalRegeneron Pharmaceuticals; Ohio State UniversityNot yet recruiting
-
University of MichiganRegeneron PharmaceuticalsRecruiting
-
University of California, San FranciscoRecruiting
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAsthma; EosinophilicSpain
-
Montefiore Medical CenterRegeneron PharmaceuticalsRecruitingChronic Rhinosinusitis With Nasal PolypsUnited States
-
Johns Hopkins UniversityDoris Duke Charitable FoundationNot yet recruitingAtopic Dermatitis
-
Northwestern UniversityRecruitingSkin DiseasesUnited States
-
SanofiRegeneron PharmaceuticalsRecruiting